Real world use of long-acting cabotegravir and rilpivirine in a HIV centre in Hong Kong

被引：0
|
作者：
Chan, M. C. J. [1 ]
Chik, S. H. T. [1 ]
Lamb, S. S. [1 ]
Choi, Y. C. C. [1 ]
Lau, W. T. A. [1 ]
Leung, C. S. E. [1 ]
To, P. Y. L. [1 ]
Lau, P. L. D. [1 ]
Tsang, T. Y. O. [1 ]
机构：
[1] Hosp Author Infect Dis Ctr, Hong Kong, Peoples R China
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
814
引用
收藏
页码：155 / 156
页数：2
相关论文
共 50 条
  • [31] Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir/rilpivirine
    Hill, Lucas A.
    Abulhosn, Kari K.
    Yin, Jeffrey F.
    Bamford, Laura P.
    AIDS, 2023, 37 (04) : 605 - 609
  • [32] The use and utility of toolkits in supporting cabotegravir plus rilpivirine long-acting implementation in the CARISEL (Cabotegravir And Rilpivirine Implementation Study in European Locations) study
    Trehan, Rekha
    Gutner, Cassidy
    Okoli, Chinyere
    Ghosn, Jade
    Vera, Francisco
    Florence, Eric
    Lutz, Thomas
    van der Valk, Marc
    Czarnogorski, Maggie
    HIV MEDICINE, 2023, 24 : 93 - 93
  • [33] Clinical and pharmacological outcomes of real-world use of Long-Acting Cabotegravir and Rilpivirine in France: Efficacy and tolerance during the first 72 weeks
    Psomas, C. K.
    Halfon, P.
    Salnikova, M.
    Khiri, H.
    Tichadelle, F.
    Allemand, J.
    Neant, N.
    Solas, C.
    Philibert, P.
    HIV MEDICINE, 2023, 24 : 81 - 82
  • [34] Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable Antiretroviral therapy feasiBility Study (JABS)
    John, M.
    Williams, L.
    Nolan, G.
    Bonnett, M.
    Castley, A.
    Nolan, D.
    HIV MEDICINE, 2024, 25 (08) : 935 - 945
  • [35] Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study
    Bettonte, Sara
    Berton, Mattia
    Stader, Felix
    Battegay, Manuel
    Marzolini, Catia
    CLINICAL INFECTIOUS DISEASES, 2024, 79 (02) : 477 - 486
  • [36] Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
    Daryl Hodge
    David J. Back
    Sara Gibbons
    Saye H. Khoo
    Catia Marzolini
    Clinical Pharmacokinetics, 2021, 60 : 835 - 853
  • [37] The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions
    Rusconi, Stefano
    Santoro, Maria M.
    Capetti, Amedeo F.
    Gianotti, Nicola
    Zazzi, Maurizio
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 60 (03)
  • [38] A cautionary note on entry and exit strategies with long-acting cabotegravir and rilpivirine
    Ripamonti, Diego
    Rusconi, Stefano
    Zazzi, Maurizio
    AIDS, 2024, 38 (02) : 263 - 265
  • [39] Long-Acting Cabotegravir for HIV/AIDS Prophylaxis
    Engelman, Kathleen D.
    Engelman, Alan N.
    BIOCHEMISTRY, 2021, 60 (22) : 1731 - 1740
  • [40] Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals
    Cossu, Maria Vittoria
    Cattaneo, Dario
    Moschese, Davide
    Giacomelli, Andrea
    Soloperto, Sara
    D'Avolio, Antonio
    Antinori, Spinello
    Gori, Andrea
    Rizzardini, Giuliano
    Gervasoni, Cristina
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (05) : 1126 - 1132
12345